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The opioid epidemic in the United States remains a serious public health concern with severe negative consequences for the individuals 
struggling with addiction, their families, and surrounding communities. 
In 2016, the most recent year for which data are available, more than 11 
million people misused prescription opioid medication and more than 
42,000 individuals died as a result of an opioid overdose (i.e. overdose 
from prescription opioids, heroin, and fentanyl).1,2 In recognition of the 
devastating impact of opioid abuse, in October 2017, the Acting Secretary 
of Health and Human Services declared the opioid crisis a public health 
emergency.3 
Faculty and staff within the Law & Health Care Program at the University 
of Maryland Francis King Carey School of Law have been actively 
engaged in research, clinical work, and advocacy related to the epidemic. 
Professor Amanda Pustilnik recently completed an analysis of the origins 
of the epidemic and conditions, particularly the legal and policy factors, 
which contributed to its spread. Her research on the epidemic was included 
as a chapter in the Aspen Institute’s report “Confronting Our Nation’s 
Opioid Crisis,” published in late 2017.4  (Continued on next page)
From the Director
This has been a busy year for the Law & Health Care Program. 
We celebrated the 20th Anniversary of the Journal of Health Care 
Law & Policy, hosted the 7th Annual Health Law Regulatory 
and Compliance Competition, welcomed 2018 Rome Lecturer, 
Dr. Aaron Kesselheim of the Harvard School of Medicine, and 
collaborated with the Johns Hopkins Berman Institute of Bioethics 
on a joint faculty retreat. In this issue, we also highlight the work on 
the opioid epidemic of L&HCP faculty, as well as faculty and staff 
from our affiliate programs, the Center for Health and Homeland 
Security and the Legal Resource Center for Public Health Policy. 
We hope you enjoy our Summer Issue.
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In “The Law’s Responses to the 
Opioid Epidemic,” Pustilinik provides 
a comprehensive overview of the 
events (namely approval of OxyContin 
in 1996), agencies (FDA, DEA, CMS, 
among others) and laws (such as 
the Controlled Substances Act) that 
have played a part in the increased 
use of opioids and subsequent spike 
in rates of addiction and overdose. 
As Pustilnik notes, the “large set of 
actors, with quite disparate mandates, 
powers and policies can create 
inconsistencies and coordination 
problems in responding to the national 
drug epidemic.”4 At the same time, 
however, this complex framework 
provides opportunity for innovative 
legal approaches.
At the federal level, there was a push 
during the Obama Administration 
to integrate efforts in the health 
and criminal law contexts with an 
emphasis on treatment and improved 
care, an acknowledgement that 
previous efforts focused on punitive 
measures and incarceration had been 
ineffective in addressing the crisis. 
Under the current administration, the 
future direction of federal policy is 
unclear. As a result, much of the push 
for innovative approaches to the opioid 
epidemic is occurring at the state 
level. There is, for example, increasing 
reliance on data to allow states to 
identify troubling prescription patterns 
and high-risk areas and individuals. 
Prescription drug monitoring programs 
(PDMPs) are one example of this type 
of data-driven initiative. States are 
able to identify providers engaged in 
questionable prescribing practices as 
well as patients who may be doctor 
shopping. 
Other efforts at the state level include 
increased funding and expanded 
access to medication-assisted 
treatment, such as methadone, which 
has demonstrated higher effectiveness 
than more conventional addiction 
recovery programs. Harm reduction is 
another increasingly popular approach 
among legislators. Safe injection 
facilities that allow individuals to 
use drugs under medical supervision 
have been opened in West Virginia 
and Washington State with similar 
legislation pending in several 
other states. Other legislative harm 
reduction strategies include so-called 
Good Samaritan and safe harbor 
laws that are designed to encourage 
individuals to seek assistance in the 
case of drug overdose without fear 
of criminal prosecution or other legal 
repercussions. 
There remain, however, significant 
legal obstacles to local, state and 
federal efforts to curb opioid abuse. 
These include conflicts between these 
new legislative efforts and existing 
federal laws grounded in an outdated 
perspective on drug addiction as 
a moral failure and a voluntary 
behavior that governments should 
not incentivize through provision of 
treatment services. 
Evidence of substance abuse can 
prevent access to social services 
programs such as Medicaid, the 
Supplemental Nutritional Assistance 
Program and Temporary Assistance for 
Needy Families. According to Prof. 
Pustilnik’s analysis, as of March 2017, 
fifteen states mandated drug testing for 
recipients of state-administered federal 
benefit programs. Such rules have 
an inherent conflict with evidence-
based approaches to the epidemic that 
emphasize access to treatment. 
Prof. Amanda Pustilnik
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As Pustilnik notes, opioid 
manufactures have been able to reap 
tremendous profits through product 
sales but do not bear any of the costs 
associated with improper use and 
abuse of that product. That cost is 
borne largely by state and federal 
government and ultimately taxpayers. 
Pustilnik argues that lawmakers 
should adopt approaches that have 
been successful for other public 
health issues such as tobacco, drunk 
driving, and environmental pollution. 
These models, she argues, have been 
successful in their ability to align 
commercial interest with the public 
interest by establishing penalties 
and other sanctions that will provide 
incentives for responsible corporate 
behavior. She likens pharmaceutical 
companies to bar operators – once 
civil and criminal penalties were 
imposed and enforced on operators 
for selling excess amounts of alcohol 
to patrons. Approaches that rely on 
individual court cases, however, are 
unlikely to have a large-scale deterrent 
effect. 
The Tobacco Master Settlement 
Agreement serves as another potential 
model. There are clear parallels 
between the tobacco and opioid 
industries – misrepresentations 
of product risks and aggressive 
marketing, among others. The 
Settlement provides significant 
compensation to states and places 
strict restrictions on tobacco 
marketing. Such a model could be 
employed in the opioid context as 
well. The model’s strengths lie in its 
ability to begin to shift the costs of 
the epidemic back to manufacturers 
and may serve as a more effective 
national strategy versus a case-by-case 
litigation approach.
The epidemic of opioid abuse must 
be addressed at all levels, i.e., local, 
state and federal, with a multifaceted 
approach that includes public health 
and medical professionals as well as 
policy, judicial, and law enforcement 
entities. In order to adequately address 
the root causes of the epidemic, 
however, Pustilnik makes a convincing 
argument that legal approaches 
must focus on the actions of drug 
manufacturers.
University of Maryland Center for 
Health & Homeland Security Aids in 
Maryland’s Response
In Maryland, opioid-related deaths 
nearly quadrupled between 2010 and 
2016 (final numbers for 2017 are still 
pending but suggest that rates continue 
to rise). In response, in March 2017, 
Maryland Governor Larry Hogan 
declared the opioid addiction crisis 
a state of emergency. Since the 
declaration, the staff at the University 
of Maryland Center for Health and 
Homeland Security (CHHS) has 
been actively engaged in a statewide, 
multiagency effort to combat and 
prevent opioid addiction, overdose and 
death. 
CHHS staff member Birch Barron is 
currently serving as Deputy Director 
and Chief of Staff to Clay Lance, 
the Senior Emergency Management 
Advisor to the Governor, at the 
Opioid Operational Command Center 
(OOCC), the body responsible 
for coordinating the state’s opioid 
response. Prior to the establishment 
of the OOCC, many agencies at the 
state and local level were working 
to address the opioid epidemic but 
there was little communication or 
coordination between agencies or 
dissemination of best practices and 
lessons learned. 
The OOCC provides statewide 
coordination of the many stakeholders 
involved in addressing the crisis, 
including the Maryland Emergency 
Management Agency (MEMA), the 
Maryland Department of Health 
(MDH) as well as ten other state 
agencies and representatives from all 
twenty-four counties in the state. 
Other members of the CHHS team 
are also contributing to the effort. 
Trudy Henson ‘08, CHHS Public 
Health Program Director, and Michael 
Tennison ‘15, Senior Law & Policy 
Analyst, have been collaborating 
with MEMA and the OOCC to write 
the OOCC review and transition 
report. The report examines activities 
undertaken since the declaration, 
identifies the legal issues that may 
arise during a transition out of the 
state of emergency and provides a 
framework for that transition. The 
report was completed in late February 
but has not yet been released to the 
public. 
Maryland’s approach to the opioid 
crisis, as a state of emergency rather 
than a public health emergency, raises 
many legal and policy issues. Trudy 
Henson examines these with students 
in her course Law and Policy of 
Emergency Public Health Response. 
Prof. Henson notes, “One reason 
that Maryland chose to address the 
opioid crisis under a general state of 
emergency is that such a declaration 
gives the Maryland Emergency 
Management Agency jurisdiction and 
one of MEMA’s strengths is its ability 
to coordinate resources as well as 
its incident command structure that 
provides a ready-made framework for 
the response. This approach recognizes 
that the opioid crisis is not only a 
public health issue but a problem that 
has wide repercussions for education, 
housing, and law enforcement among 
Trudy Henson
(Continued on page 5)
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What about treatment for chronic pain?
In all of the debate surrounding the opioid epidemic, an important segment of the 
population is often forgotten – patients suffering from chronic pain for which opioid 
medication remains the only effective treatment. Diane Hoffmann, Professor and Director 
of the Law & Health Care Program, has a longstanding research interest in the treatment of 
chronic pain. In 1997, Hoffmann was named a Mayday Scholar by the Mayday Foundation, 
an organization dedicated to alleviating the incidence and consequence of chronic pain. As 
a result of that award, she has been able to examine the issue in depth and make important 
contributions to the literature regarding the legal obstacles to the treatment of pain. 
Hoffmann continues to examine the impact of the latest policy developments resulting 
from the opioid epidemic. In fall 2017, she spoke to clinicians and researchers during Pain 
Grand Rounds in the Department of Neurology and Neurosurgery at the Johns Hopkins 
School of Medicine. In her talk “Legal and Ethical Challenges to the Treatment of Chronic 
Pain Patients,” Prof. Hoffmann reviewed the collateral damage of prior attempts to address 
the issue of opioid overprescribing, namely disciplinary and prosecutorial actions against 
physicians treating chronic pain patients within the standard of care. This was due in part 
to a lack of understanding of chronic pain treatment on the part of federal agencies and 
state licensing boards responsible for oversight of physicians. Indeed, these entities have 
struggled to establish and enforce a consistent standard for opioid prescriptions.
At the same time, there has been considerable pressure for state and federal agencies to 
respond to the rapid increase in rates of opioid misuse and abuse. After many years without 
a consistent policy, in 2016, the CDC issued guidelines for prescribing opioids to treat 
chronic pain. The guidelines emphasize the importance of prescribing only when necessary, 
at the lowest dose and for the shortest duration possible and only in the context of close 
patient monitoring. The guidelines have spurred legislative action in many states and include 
efforts to limit dosage and quantity of opioid prescribing. Many state Medicaid Programs 
have also adopted the CDC guidelines and DEA has stepped up its enforcement, with a 
significant increase in the number of administrative actions against physicians to remove 
their registration to prescribe controlled substances as well as criminal prosecutions.
“I think it’s clear now in hindsight that the policy pendulum swung too far in the direction 
of liberalization of opioid prescribing. Now I fear the pendulum is swinging too far in the 
direction of restrictiveness,” said Hoffmann. “In the effort to combat the opioid epidemic, 
state and federal authorities are depriving patients of an appropriate and effective treatment 
for chronic pain.” Recently, Hoffmann co-wrote a letter to the editor of the Washington Post, 
making these points in response to an op-ed criticizing an effort by Human Rights Watch 
to look at the effects of opioid limits on the treatment of chronic pain (see Hoffmann and 
Nicholson, Reasonable Questions on Opioids, Washington Post, May 16, 2018). 
Law & Health Care Program
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many others.” 
Local Level Approaches: The Legal 
Resource Center for Public Health 
Policy
The Legal Resource Center for Public 
Health Policy (LRC), led by Professor 
Kathleen Hoke, has been working 
in the area of addictions since its 
founding in 2001. Originally created 
with funds from Maryland’s settlement 
with tobacco companies, the Center 
provides legal guidance to state and 
local governments, lawmakers, non-
governmental organizations and health 
advocacy groups. In the nearly twenty 
years that the Center has been working 
with local health officers, its attorneys 
and staff have developed a 
strong reputation as a reliable 
resource for legal and 
technical assistance. As local 
agencies started to confront 
the opioid epidemic, they 
began contacting the LRC 
for assistance. 
Much of LRC’s work in the 
context of opioids focuses on 
the tracking of legislation in 
Maryland and nationally. The 
LRC, along with students 
from the law school’s Public 
Health Law Clinic, provides 
concise summaries of all opioid 
legislation introduced during the 
Maryland legislative session as well 
as weekly updates of each bill’s status, 
hearing dates, etc. The LRC also holds 
biweekly conference calls during 
the legislative session that provide 
stakeholders the opportunity to ask 
questions about specific bills and share 
information. 
In the 2017 legislative session, 
more than sixty opioid bills were 
introduced in the Maryland General 
Assembly. With such a high volume 
of legislation, this tracking provides 
critical support to local agencies 
and organizations working to 
improve public health. It also helps 
to inform LRC’s work with the 
Opioid Workgroup of the Health and 
Government Operations Committee of 
the Maryland General Assembly. 
In addition to the legislative tracking, 
LRC staff and student attorneys are 
frequently called upon by lawmakers 
to provide background research on 
opioid-related initiatives in other 
states. A state delegate, for example, 
recently contacted the LRC to find 
out what other states are doing to 
encourage pregnant women to seek 
treatment for opioid addiction. This is 
a difficult population to reach given 
the stigma associated with addiction 
and fears that child protective services 
will become involved. 
Outside of the legislative session, 
the LRC team spends time working 
with local health departments, 
giving presentations on the latest 
developments in public health policy 
at the state and national level. They 
also work closely with the judiciary, 
conducting educational sessions and 
developing materials to inform judges 
of policy changes (e.g. changes in 
insurance coverage requirements) 
that might influence decisions in the 
sentencing phase of trials. 
LRC Staff Attorneys Mellissa 
Sager and Brooke Torton work 
with the Baltimore Area Health 
Education Center to offer semiannual 
Interprofessional Education Training 
to students from the University of 
Maryland Baltimore professional 
schools (Law, Medicine, Pharmacy, 
Dentistry, Social Work, and Nursing). 
Students analyze case studies, discuss 
recent policy changes (e.g. Maryland’s 
Good Samaritan Law which provides 
legal protection to individuals to 
encourage emergency service contact 
in case of overdose) and receive 
training in the administration of 
Naloxone to prevent opioid overdose 
deaths. 
Professor Hoke is also engaged in 
activities at the campus level through 
the University’s Center for 
Addiction Research, Education 
and Services (CARES), an 
interprofessional effort to 
address the adverse impact of 
addiction. Hoke serves on the 
Steering Committee where 
she contributes her expertise 
in policy advocacy to inform 
the Center’s efforts to provide 
addiction-related policy 
consultation and analysis to 
local and state government 
policy makers. 
Through scholarship, advocacy 
and technical assistance, Law & 
Health Care Program faculty, staff 
and students are making important 
contributions to local, state and 
national level efforts to address the 
epidemic of opioid abuse and remain 
committed to finding solutions. Multi-
level, multidisciplinary approaches 
that include a health law perspective 
will be essential to these efforts. 
(Continued on page 12)
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The Journal of Health Care Law & Policy recently celebrated its 20th Anniversary 
with a dinner attended by faculty, current student 
editors and alumni. The night was highlighted by 
recollections from faculty on the Journal’s history 
and accomplishments and from alumni on their 
experiences working on the student-led publication.
After welcoming attendees, current Editor-In-
Chief Hassan Sheikh and Managing Editor Eleanor 
Chung introduced Professor Karen Rothenberg who 
reflected on the Journal’s founding. She talked about 
the initial vision behind the creation of the Journal, 
a publication designed to disseminate the latest 
research of leading scholars working in the area 
of health law and policy. It also served the important 
purpose of providing students with exposure to the latest 
scholarship on leading issues in health law such as the Supreme Court's decision in the Cruzan case and implications 
of the AIDS epidemic for health care workers. Initially used solely to publish articles generated from symposia hosted 
by the Law & Health Care Program, after a few years the Journal was able to dedicate one issue per year to unsolicited 
articles, cementing its status among legal academics in the field as well as interdisciplinary scholars and policy makers. 
Law & Health Care Program Director and Professor Diane Hoffmann then offered remarks on the Journal’s many 
accomplishments over the past two decades including its role as a resource for policy makers on cutting-edge issues. 
The first issue published by the Journal, for example, focused on conducting medical research with individuals lacking 
decision-making capacity and included articles by leading bioethicists and clinicians. Articles from the issue were later 
cited by the National Bioethics Advisory Commission in its report on Research Involving Persons with Mental Disorders 
that May Affect Decision-making Capacity.  
Hoffmann noted that the Journal has also successfully established itself as a forum for 
the publication of multidisciplinary perspectives on pressing topics in health law and 
policy, attracting not only health lawyers but also medical researchers, physicians, 
legislators, practicing lawyers, policy makers, bioethicists, industry representatives, and 
patient advocates. 
This multidisciplinary approach became the model for the Journal’s symposium issues. 
The Journal has published 27 symposium issues based on Health Law Conferences and 
Roundtables as well as 13 articles from the endowed Stuart Rome lecture. These have 
included manuscripts by Prof. Lawrence Gostin from Georgetown University, Prof. 
William Sage from University of Texas, Prof. Robert Burt and more recently, Prof. Abbe 
Gluck, from Yale Law School, Nancy-Ann DeParle, the former director of the Centers 
for Medicare and Medicaid Services, and Daniel Levinson, Inspector General for the 
U.S. Dept. of Health and Human Services, among others. Hoffmann concluded by 
praising the Journal for providing students with an invaluable opportunity to learn from 
leading scholars about many different areas of health law and policy. 
Former Editors-in-Chief Adrian Wilairat ’06, now Writer-Editor for the U.S. Department of Justice at the Office for 
Victims of Crimes, and Deepti Kulkarni ’08, an associate attorney at Sidley Austin, echoed Professor Hoffmann’s 
sentiments, sharing their reflections on their experience working on the Journal and expressing gratitude for the skills 
Journal of Health Care Law & Policy 
Celebrates 20th Anniversary
Faculty, alumni, and student-editors gather at the Journal's 
anniversary dinner.
Deepti Kulkarni ’08
Law & Health Care Program
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Award of Scholarly Excellence 
(Awarded to individuals who published the most cited publications) 
• Paul Steven Miller, Is there a Pink Slip in My Genes? Genetic Discrimination in the Workplace 
• Sara Rosenbaum, Medicaid at Forty: Revisiting Structure and Meaning in a Post-Deficit Reduction Act Era 
• Robert A. Mikos, Preemption Under the Controlled Substances Act 
• Theresa Glennon, The Stuart Rome Lecture: Knocking Against the Rocks: Evaluating Institutional Practice and the 
African-American Boy 
• Paul Arshagouni, “But I’m an Adult Now … Sort of” Adolescent Consent in Health Care Decision-Making and the 
Adolescent Brain 
• Elizabeth Tobin Tyler, Allies Not Adversaries: Teaching Collaboration to the Next Generation of Doctors and Lawyers 
to Address Social Inequality 
• Jennifer L. Pomeranz, Compelled Speech Under the Commercial Speech Doctrine: The Case of Menu Label Laws 
• Deborah Kaplan, The Definition of Disability: Perspective of the Disability Community 
• Adrian Wilairat, Faster, Higher, Stronger? Federal Efforts to Criminalize Anabolic Steroids and Steroid Precursors 
• Ellen A. Callegary, The IDEA’s Promise Unfulfilled: A Second Look at Special Education & Related Services for 
Children with Mental Health Needs After Garret F
Award of Scholarly Excellence - Student Publications
(Awarded to individuals who published the most cited student publications) 
• Adrian Wilairat, Faster, Higher, Stronger? Federal Efforts to Criminalize Anabolic Steroids and Steroid Precursors 
• Erin Myers, The Manipulation of Public Opinion by the Tobacco Industry: Past, Present, and Future 
• Carrie A. Roll, The Human Papillomavirus Vaccine: Should It Be Mandatory or Voluntary? 
• Jake Schaller, Not for Bathing: Bath Salts and the New Menace of Synthetic Drugs 
• Lucy W. Shum, Educationally Related Mental Health Services for Children with Serious Emotional Disturbance: 
Addressing Barriers to Access Through the IDEA 
• Amanda S. Pitcher, Contrary to First Impression, Genes are Patentable: Should There be Limitations? 
• Samantha Schad, Adolescent Decision Making: Reduced Culpability in the Criminal Justice System and Recognition 
of Capability in Other Legal Contexts 
• Sara Klemm, Keeping Prevention in the Crosshairs: A Better HIV Exposure Law for Maryland 
• Michael J. McKeefery, A Call to Move Forward: Pushing Past the Unworkable Standard That Governs Undocumented 
Immigrants’ Access to Health Care Under Medicaid 
• Anne Erikson Haffner, The Increasing Necessity of the Tort System in Effective Drug Regulation in a Changing 
Regulatory Landscape
M. Jason Brooke
Rebecca Wizeman Hall
Deepti A. Kulkarni
Melissa M. McDonnell
Marc A. Nardone
Scott D. Nelson
Michael J. Pappas
Melanie Santiago
Amy F. Siegel
Sally Terese Vecchio
Nisha Wagle
Adrian Wilairat
Citation for Outstanding Service 
(Awarded to Editors-in Chief who published the ten most cited publications) 
developed during their respective tenures. Current faculty advisor to the Journal, Professor Frank Pasquale, then shared his 
thoughts on the bright future ahead for the Journal. The speakers were followed by the presentation of awards to authors 
and student contributors who published the most cited publications in the Journal. The Editors-In-Chief who marshalled 
these important manuscripts to publication were also recognized. A complete list of awardees is included below.
Pg 8
Dr. Aaron Kesselheim Delivers 2018 Rome 
Lecture on Drug Pricing
On March 8, 2018, the Law & 
Health Care Program and the 
Center on Drugs and Public 
Policy at the University of 
Maryland School of Pharmacy 
co-sponsored the 2018 Stuart 
Rome Lecture and follow 
on panel, “Drug Pricing and 
Prospects.” The Stuart Rome 
Lecture was established in 1984 
to honor the memory of Stuart 
Rome, a prominent health law 
attorney, community activist, 
art patron, and humanitarian in 
the Baltimore Area. This year’s 
lecture was delivered by Aaron 
Kesselheim, MD, JD, MPH. 
Dr. Kesselheim is the Director 
of the Program on Regulation, 
Therapeutics and Law 
(PORTAL) in the Division 
of Pharmacoepidemiology & 
Pharmacoeconomics, Department 
of Medicine, Brigham and 
Women’s Hospital as well as an 
Associate Professor of Medicine 
at Harvard Medical School. 
His research focuses on the 
effects of intellectual property 
laws and regulatory policies on 
pharmaceutical drug development 
and the cost and availability of 
prescription drugs.
Drug prices have increased 
dramatically in recent years. In 
2015, prescription drug spending 
in the United States increased 
by 12% and again by 6% in 
2016 to a total of $450 billion, 
accounting for one-fifth of all 
health care spending. The bulk of 
this money is directed to brand 
name drugs, which account 
for 72% of all drug spending 
although they comprise only 
10% of prescriptions. Generic 
drug prices have also increased 
dramatically. Dr. Kesselheim provided 
a detailed overview of the current 
state of prescription drug pricing in 
the U.S. and the clinical consequences 
of increases, including lower patient 
adherence when more expensive brand 
name drugs are prescribed instead of a 
more affordable generic.
He then dispelled several myths 
about price increases such as industry 
arguments that such increases are 
necessary to support innovation. 
Kesselheim noted that there is no 
association between research and 
development costs and drug prices. 
Most research and development 
for new drug products is conducted 
in academic institutions receiving 
public funding from entities such as 
the National Institutes of Health. In 
addition, according to an analysis 
conducted by Dr. Kesselheim and 
Dr. Ameet Sarpatwari ‘13, drug 
manufacturers spend only 10-20% of 
revenue on research and development 
in contrast to 20-30% on marketing 
and administration costs and the 20-
30% paid to shareholders.
Kesselheim also disputed the assertion 
that onerous regulatory hurdles at 
the FDA are driving price increases, 
noting widespread use of expedited 
approval pathways by the majority 
of new drugs as well as faster FDA 
approval times than counterparts in 
Europe and Canada.
Kesselheim asserted that drug prices 
are rising because pharmaceutical 
companies are allowed to charge 
whatever the market will bear while 
employing strategies that undercut 
competition and hinder the ability of 
payers to provide counterweights that 
might reduce high prices. He then 
discussed various policy solutions 
that might be employed based on 
where the drug product is in the drug 
development "life cycle."  
Market Exclusivity Period
In the initial post approval period, new 
brand-name drugs are guaranteed six 
to seven years of market exclusivity 
with longer periods granted for new 
antibiotics and biologics. Drugs also 
enjoy patent protections. In addition 
to the advantages of exclusivity, 
Dr. Aaron Kesselheim delivers Rome Lecture.
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manufacturers further benefit from 
limits on public payers. Medicare, for 
example, is unable to negotiate drug 
prices. Private payers are also limited in 
their ability to negotiate lower prices, 
primarily due to the lack of comparative 
effectiveness data available at the 
time of approval as well as state law 
coverage requirements.
Kesselheim offered several 
countermeasures to the problem such as 
authorization for public payers to use 
formularies and negotiate drug prices 
(currently prevented under the Medicare 
Part D statute) or use international 
reference pricing so that U.S. drug 
prices remain in line with what other 
countries are paying manufacturers. 
There are additional policy 
opportunities at the provider level to 
address drug pricing as evidenced by 
California’s recent effort to prohibit 
manufacturer coupons and discounts 
for brand name drugs when a generic 
is available. While the consumer is 
shielded from price increases via 
copay coupons, payers must pay for 
the increases associated with these 
drugs. Other efforts at the provider 
level include integration of value-based 
prescribing into professional education 
or through electronic medical record 
point-of-care reminders.
Transition From Brand Name to 
Generic
Kesselheim noted that the availability 
of generic versions of brand-name 
products is the most important factor 
in drug pricing. As brand name drugs 
reach the end of their market exclusivity 
period, however, manufacturers have 
become adept at taking steps to extend 
exclusivity through, for example, 
payments to generic producers in 
exchange for dropping lawsuits to 
gain market access or the development 
of “a thicket of secondary patents.” 
Other strategies include manufacturer 
refusal to provide samples to generic 
manufacturers, which are required to 
conduct bioequivalence studies. 
At this stage in the life cycle, 
Kesselheim sees several opportunities 
for reducing drug prices including a 
review of settlements between generic 
and brand name manufacturers. 
Generic Competition Phase
Once the exclusivity period ends, 
generic manufacturers enter the market 
and, in theory, competition between 
them drives down prices. In practice, 
Kesselheim noted, there are fewer 
competitors in the U.S. market than in 
other countries. He proposed several 
solutions to address the lack of market 
competition including importation of 
generics from well-regulated markets  
in other countries and changes to 
the regulatory framework that can 
stimulate increased competition 
such as expedited review of generic 
applications when there are three or 
fewer drugs in the market. 
There is a pressing need to address the 
cost of prescription drugs, Kesselheim 
concluded, as increasing prices 
will continue to result in negative 
consequences for patients and the 
entire health system. Dr. Kesselheim’s 
lecture was followed by a panel 
of experts on pharmaceutical drug 
pricing. 
Frank Palumbo, JD, PhD, Executive 
Director of the Center on Drugs 
and Public Policy at the University 
of Maryland School of Pharmacy, 
provided an overview of pharmacy 
Drs. Frank Palumbo and Bill Padula (l.)
benefit managers and their role in drug 
costs. 
Joshua Auerbach, Esq., Special 
Assistant & Senior Litigation Counsel, 
Maryland Office of the Attorney 
General, discussed the Maryland anti-
price gouging statute and subsequent 
litigation brought by generic 
manufacturers. The Maryland statute 
was challenged shortly after it passed 
in 2017 by the professional association 
of generic drug manufacturers 
(Association for Accessible Medicines 
v. Frosh). In April 2018, a three-
judge panel of the U.S. Court of 
Appeals for the Fourth Circuit held 
that the Maryland statute violates the 
dormant commerce clause by directly 
regulating the price of transactions 
outside of the state. Maryland Attorney 
General Brian Frosh has requested that 
the full court rehear the case. 
William V. Padula, PhD, MS, MSc, 
Assistant Professor, Department of 
Health Policy & Management, Johns 
Hopkins Bloomberg School of Public 
Health, provided an overview of 
approaches other states have taken to 
stem increases in prescription drug 
costs. Finally, Ameet Sarpatwari, 
JD (‘13), PhD, Assistant Director of 
PORTAL, discussed the market for 
biologics and biosimilars, noting that 
FDA has approved few biosimilars, 
making competition in the biologics 
space unlikely.
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Clinic Spotlight: Civil Rights of 
Persons with Disabilities Clinic
Students with interest in health 
law have several options available 
to them in order to obtain 
professional experience during 
their studies including three 
health law clinics and more than 
two dozen externship placement 
opportunities. The Civil Rights of 
Persons with Disabilities Clinic, 
one of the oldest disability rights 
clinics in the country, has been 
providing legal services to clients 
with disabilities since 1975.  
Clinic History
Professor Emeritus Susan Leviton 
founded the clinic, then called 
the Developmental Disabilities 
Clinic, the same year that 
Congress passed the Education 
for All Handicapped Children Act 
(later renamed the Individuals 
with Disabilities Education Act, 
or IDEA). The law required all 
public schools to provide children 
with disabilities equal access to 
education and mandated provision 
of special services to meet the 
specific needs of children with 
disabilities. That statute came 
two years after the passage of the 
Rehabilitation Act of 1973, the 
first federal civil rights law for 
individuals with disabilities. The 
EAHCA gave parents a role in the 
educational process and facilitated 
parental involvement with schools 
to identify and secure what their 
children needed to be successful. 
Professor Leviton recalls, “These 
laws, the Rehabilitation Act 
and the EAHCA, marked the 
beginning of a new era. Prior to 
their passage, parents of children 
with disabilities were encouraged 
to institutionalize them. This was a 
completely new area of the law and a 
tremendous learning opportunity for 
our students.” 
In 1983, Professor Stanley Herr, a 
longtime disability advocate, joined 
the law school faculty and assumed 
leadership of the clinic. Professor 
Herr’s contributions to disability 
rights are well documented. In 
the early 1970s, he served as lead 
counsel in Mills vs. Board of 
Education where the legal team 
successfully argued for access to 
public education for all children 
including those with disabilities. 
That landmark decision later 
provided the foundation for the 
EACHA. By all accounts, Herr 
was an indefatigable disability 
rights advocate, receiving honors 
from many organizations in his 
career including The ARC and the 
American Bar Association.
Through their work with the 
Maryland Disability Law Center 
(now Disability Rights Maryland), 
Prof. Herr befriended Marc 
Charmatz, an attorney with the 
National Association of the 
Deaf (NAD), a grassroots civil 
rights advocacy organization that 
represents deaf and hard of hearing 
individuals. In 1999, when Herr took 
a sabbatical from the law school, he 
asked Charmatz to lead the clinic in 
his absence. Sadly, Prof. Herr was 
unable to return to his role, dying 
from cancer in 2001. 
Prof. Charmatz carried on Herr’s 
legacy and assumed leadership of 
the clinic for the next 18 years. 
During that time, he continued to 
serve as litigation counsel at NAD 
and began to combine his work there 
with his work at the clinic. Charmatz 
recalls, “While I have tremendous 
respect for those engaged in work at the 
policy level, I am client-driven - I want 
to represent individuals, particularly 
those having difficulty finding counsel. 
I knew we had plenty of clients in need 
of representation at NAD. I realized 
that working in collaboration with 
NAD would be a great educational 
tool to teach students about real-world 
legal representation in the context of 
disability rights.”
In recognition of his contributions, 
Charmatz’s work as an advocate 
for individuals with disabilities was 
recently featured in an article in the 
ABA Journal magazine discussing 
Professors Stanley Herr and Diane Hoffmann, 
circa 1995
Professor Emeritus Susan Leviton
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the origins and achievements of the 
disability rights movement. 
In 2014, Charmatz recruited Caroline 
Jackson, Staff Attorney with NAD, 
to serve as co-instructor. He stepped 
down from his role directing the clinic 
after the Spring 2017 semester; Anna 
Bitencourt joined as clinic co-director 
in fall 2017. Prof. Bitencourt currently 
serves as a staff attorney and Director 
of Intake at NAD. 
Prof. Jackson joined the NAD as a 
Skadden Fellow after law school. 
Long interested in disability rights, 
Jackson worked as a sign language 
interpreter in New York City before 
returning to school to pursue her 
law degree. Prof. Bitencourt, who 
is deaf, worked in private practice 
for several years after law school 
and occasionally received referrals 
or requests for assistance in cases 
involving deaf clients from the NAD. 
She began working at NAD part-
time and was then invited to join the 
organization on a full-time basis to 
direct client intake and litigate cases.
Training Students to Advocate for 
Civil Rights
Jackson and Bitencourt work with 
student attorneys to represent clients 
with disabilities in a variety of 
settings and collaborate with other 
organizations involved in broad impact 
litigation. 
The classroom component of the 
clinic provides students with a 
foundation in disability law including 
the Americans with Disabilities Act, 
the Rehabilitation Act as well as 
related laws in the areas of education, 
employment and public benefits. 
Clinic students handle cases at all 
stages of legal proceedings, including 
initial client interviews, drafting 
pleadings, counseling, discovery, 
motions practice, trial and appeal. 
Through their participation in the 
clinic, they develop an understanding 
of the public policy issues that 
influence the ability of individuals 
with disabilities to participate 
in society as well as the various 
stakeholders involved in protecting 
and promoting disability rights.
Many of the cases students handle 
address issues of communication 
access for deaf and hard of hearing 
individuals. Deaf and hard of hearing 
individuals and their family members 
face obstacles in a variety of settings 
from schools to health care institutions 
to jails where deaf individuals lack 
access to the tools necessary to 
allow for effective communication 
and adequate engagement. Students 
participate fully in the intake process, 
receiving initial calls from potential 
clients, learning how to communicate 
with clients and obtain facts about 
their case.Students work closely 
with Ms. Bitencourt to review the 
facts of each case and determine if 
it is suitable for litigation. Caroline 
Jackson supervises the litigation 
component. 
The clinic handles a wide variety 
of cases – education, employment, 
and access to health care. Last year, 
for example, students represented 
an individual who was denied 
admission to a radiology technician 
training program because she was 
deaf. That case went to jury trial 
and was ultimately resolved in the 
client’s favor. Students also engage 
in advocacy outside the courtroom, 
drafting demand letters on behalf of 
clients to ensure that accommodations 
such as captioning and interpreters 
will be provided in various contexts. 
In addition to the nuts and bolts of 
litigation and advocacy, students 
learn about deaf culture and work 
closely with deaf professionals. 
They also learn about the protection 
and advocacy system established by 
federal law to protect disability rights. 
Many of the clinic’s student attorneys 
have continued to advocate for the 
rights of individuals with disabilities. 
Munib Lohrasbi ‘17, an alumnus of 
the law school and former student 
attorney with the clinic, was awarded 
an Open Society Institute-Baltimore 
Community fellowship to improve 
conditions for people with disabilities 
in prison in Maryland. He is working 
with Maryland’s federally mandated 
Protection & Advocacy agency, 
Disability Rights Maryland, to 
inspect state prison facilities and 
evaluate current assessment and 
accommodation procedures for 
individuals with disabilities.
Other graduates have gone on to 
hold positions at the Department of 
Justice and disability rights advocacy 
organizations in other states, a 
testament to the clinic’s lasting impact 
on students.  
Marc Charmatz
Clinic Co-Directors Caroline Jackson 
and Anna Bitencourt
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Microbiota Transplant 
Project Update
access with safety and effectiveness 
concerns. The framework requires 
increasing regulatory oversight based 
on source of stool (e.g. person known 
to patient vs. stool bank) and level 
of processing (stool vs. stool-based 
products). 
The article is available to download 
via Prof. Hoffmann’s faculty profile on 
the law school website.
Hoffmann also presented on the topic 
at an educational session held by 
the American Gastroenterological 
Association at the Crohns & Colitis 
Foundation’s Annual Meeting in Las 
Vegas in January.
seeding, where newborns delivered 
via caesarean section are swabbed 
with the mother’s vaginal fluids 
to mimic the transfer that happens 
during vaginal births. Several industry 
representatives gave presentations on 
new microbiome-based diagnostics. 
After the presentations, members 
broke into small groups to discuss 
the ethical and legal implications of 
microbiome-based diagnostics and 
therapeutics. 
The meeting was the first since 
the publication of the article, 
“Improving regulation of microbiota 
transplants,” in the journal Science in 
December 2017. That article, based 
in part on the prior working group 
meetings, proposes a framework for 
the regulation of fecal microbiota 
transplantation (FMT). Hoffmann and 
her co-authors propose a three-track 
framework that aims to balance patient 
Professor Diane Hoffmann and co-
investigators from the University of 
Maryland Schools of Law, Pharmacy 
and Medicine hosted the final meeting 
of the Microbiota Transplantation 
Working Group on February 23, 
2018. The meeting was the fourth 
in a series of meetings supported by 
Professor Hoffmann’s NIH-funded 
project, Microbiota-Transplantation: 
Recommendations for a Regulatory 
Framework. 
The working group comprises experts 
and stakeholders including physicians, 
researchers, bioethicists, lawyers, as 
well as representatives from private 
industry engaged in microbiota 
transplantation. In addition to updates 
on fecal microbiota transplantation 
(FMT) and stool-based drugs, the final 
meeting also included presentations on 
newer areas of research such as vaginal 
microbiota transplants and vaginal 
Maryland Carey Law Faculty Address the Opioid Epidemic
Continued from Page 5:
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Maryland Carey Law Teams Prevail in 
7th Annual Health Law Regulatory and 
Compliance Competition
The Seventh Annual Health Law 
Regulatory and Compliance 
Competition was held on Saturday, 
February 23, 2018 at Maryland Carey 
Law. More than 30 students from nine 
law schools competed in the event this 
year. 
Maryland Carey Law took first place 
in the competition. Team members 
(pictured above) Ashley Creech, 
Kellie Taylor, and Elias Sherlock 
were coached by Sean Gugerty ‘15 
and Samantha Collado ‘16. The 
other winning teams were American 
University Washington School of 
Law (second place) and the second 
University of Maryland team (third 
place).
Students were given 90 minutes to 
analyze a hypothetical fact pattern 
involving various interactions between 
health care stakeholders and entities 
engaged in activities that necessitate 
regulatory and compliance oversight. 
Participants then present their findings 
Maryland Carey Law students Eli Sherlock, Ashley Creech, and Kellie Taylor took first place;
 classmates Jessica Ramdat and Jennifer Ponce-Mejia placed third.  
and recommendations to a panel of 
practicing health lawyers. Nearly 
30 attorneys from a broad range 
of organizations served as judges, 
including CMS, FDA, law firms 
and private industry. This year’s 
competition focused on healthcare 
fraud and abuse, rural hospitals, 
payers, credentialing and challenges 
associated with telehealth services 
implementation, payment and 
reimbursement. 
Professor Diane Hoffmann 
commended the students for their 
participation, noting, “The competition 
provides students with a glimpse 
of real-life health law practice by 
tackling complex matters that require 
thoughtful and thorough analysis and 
a time-sensitive response. All of the 
participants should be proud of their 
performance today.”
At the luncheon following the 
competition, David Cade ‘85, CEO 
of the American Health Lawyers 
Association, provided the keynote 
address and congratulated the 
participants on both their participation 
in the competition and decision to 
pursue careers in health law. Mr. 
Cade then announced the winners and 
presented the awards. Students on the 
winning teams also received prizes 
generously donated by the American 
Health Lawyers Association and the 
Food and Drug Law Institute. 
The competition received generous 
support from the following sponsors:
Premier Sponsor: Baker Donelson
Platinum Sponsors: American Health 
Lawyers Association, Berkeley 
Research Group
Gold Sponsors: Arnold & Porter, Food 
and Drug Law Institute
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Law & Health Care Program Collaborates 
with Johns Hopkins Berman Institute of 
Bioethics on Faculty Retreat
On April 11, 2018, faculty from the Law & Health Care Program 
participated in a collaborative retreat with faculty from the Johns Hopkins 
Berman Institute of Bioethics. Although L&HCP faculty members Karen 
Rothenberg and Leslie Henry have held affiliate faculty appointments at 
the Berman Institute for many years, the retreat marked the first time that 
faculties from both programs had the opportunity to meet and discuss 
current research interests. The day’s schedule included brief presentations 
from faculty on their research in three areas: new and emerging 
technologies, infectious diseases, and opioids and pain. The presentations focused not only on current progress but 
encouraged discussion on the relationship of the different topic areas to issues of justice and the identification of research 
questions that would benefit from interdisciplinary collaboration.
“The retreat is the first of hopefully many such events bringing together the health law and Berman faculties. There 
was a lot of enthusiasm from the retreat attendees about possible collaborations. I am looking forward to the continued 
development of these ideas with our Berman colleagues,” remarked Diane Hoffmann, Director of the Law & Health Care 
Program. 
From top left: The American University team; American Health Lawyers Association CEO David Cade ‘85 
delivers the keynote adddress; Prof. Diane Hoffmann welcomes participants and judges.
7th Annual Health Law Regulatory and 
Compliance Competition
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Law & Health Care Program News
Leslie Henry
Leslie Henry was a co-author on the research white paper 
“Biorepositories: Addendum to Registries for Evaluating 
Patient Outcomes: A User’s Guide, Third Edition” prepared 
for the Agency on Healthcare Research and Quality.
Professor Henry was also a co-author on an article in the 
journal Obstetrics & Gynecology, “Ethical Considerations 
Concerning Amnioinfusions for Treating Fetal Bilateral 
Renal Agenesis,”131(1):130-134, 2018.
Diane Hoffmann
Diane Hoffmann and campus colleagues published 
“Improving Regulation of Microbiota Transplants,” in 
Science in December 2017. 
Diane Hoffmann was quoted and her article, “The Girl who 
Cried Pain,” was cited in the Atlantic on January 23, 2018 in 
the segment “Larry Nassar and the Impulse to Doubt Female 
Pain.” 
Hoffmann was a guest on NPR’s All Sides with Ann Fisher 
appearing with Abby Norman, author of Ask Me about My 
Uterus: A Quest to Make Doctors Believe in Women’s Pain 
(April 26, 2018).
The Washington Post published a Letter to the Editor by 
Hoffmann and Kate Nicholson on efforts by Human Rights 
Watch to investigate the impact of opioid limits on chronic 
pain patients (May 6, 2018).
Kathleen Hoke 
Kathleen Hoke was appointed to the Food and Drug Law 
Institute Tobacco Products Committee for 2018.
Prof. Hoke was quoted in “From Opioids to Guns: Cities, 
Counties Step Up Civil Suits,” an article published on 
Bloomberg News in March 2018.
Frank Pasquale 
Prof. Frank Pasquale was featured in the December 2017 
issue of the ABA Journal in the article “Defense lawyers 
want to peek behind the curtain of probabilistic genotyping.”
Karen Rothenberg
Prof. Rothenberg was quoted in “Is DNA testing telling us 
more than we want to know? The untold story of Ancestry.
com,” on Deseret News on May 30, 2018.
Prof. Rothenberg will serve as an Advisory Panel Member 
for a National Palliative Care Research Center Pilot and 
Exploratory Grant titled: “What it means for our family 
– Video Decision Supports for Parents Considering 
Chronic Pediatric Mechanical Ventilation,” a multicenter 
collaboration with the Johns Hopkins School of Medicine, 
the University of Mississippi Medical Center and Seattle 
Children’s Hospital.
Amanda Pustilnik
Amanda Pustilnik published “The Law’s Responses to 
the Opioid Epidemic: Legal Solutions to a Unique Public 
Health, Criminal Law, and Market-Related Crisis” in 
Confronting Our Nation’s Opioid Crisis: A Report of the 
Aspen Health Strategy Group. 
Amanda Pustilnik published “Legal Evidence of 
Subjective States: A Brain-Based Model of Chronic Pain 
Increases Accuracy and Fairness in Law,” 25 Harv. Rev. of 
Psychiatry 279 (2017).
Amanda Pustilnik published “Brain imaging tests for 
chronic pain: medical, legal and ethical issues and 
recommendations,” with Karen D. Davis, Herta Flor, 
Henry T. Greely, Gian Domenico Iannetti, Sean Mackey, 
Markus Ploner, Irene Tracey, Rolf-Detlef Treede, & Tor D. 
Wager, 13 Nature Rev. Neurology 624 (2017).
L&HCP Students
Health law student Mena Gaballah ‘18 co-authored a 
March 2018 op-ed in the Baltimore Sun with colleagues 
from the R. Adams Cowley Shock Trauma Center at the 
University of Maryland Medical Center, warning of abuse 
of the popular over-the-counter drug, Imodium. 
Public Health Law Clinic student Adrienne Thomas (3L) 
testified before the Maryland General Assembly in support 
of House Bill 315 (Maryland Cares for Kids Act), a bill 
that would require the State to cover costs associated with 
reduced breakfast and lunch to expand access for low-
income students. 
500 West Baltimore Street
Baltimore, MD 21201
www.law.umaryland.edu/healthlaw
Law & Health Care Program
Comments and letters should be 
forwarded to the above address.
The Week in Health Law Podcast
Tune in to The Week in Health Law, a weekly podcast hosted by our own 
Professor Frank Pasquale and Professor Nicolas Terry, Executive Director 
of the Hall Center for Law and Health at Indiana 
University McKinney School of Law. The podcast 
engages various guests in conversations about a 
wide range of issues in health law and policy.
To access this podcast, search for The Week in 
Health Law on your favorite podcast app. Show 
notes appear at twihl.com.
